Dietary lignans and postmenopausal breast cancer risk by oestrogen receptor status: a prospective cohort study of Swedish women by Suzuki, R et al.
Short Communication
Dietary lignans and postmenopausal breast cancer risk by
oestrogen receptor status: a prospective cohort study of
Swedish women
R Suzuki
1, T Rylander-Rudqvist
1, S Saji
2, L Bergkvist
3, H Adlercreutz
4 and A Wolk*,1
1Division of Nutritional Epidemiology, The Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden;
2Division of Clinical Trials and
Research, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan;
3The Department of Surgery and the Center for
Clinical Research, Uppsala University, Central Hospital, Va ¨stera ˚s, Sweden;
4Institute for Preventive Medicine, Nutrition, and Cancer, Folkha ¨lsan Research
Center, and Division of Clinical Chemistry, Biomedicum, University of Helsinki, Helsinki, Finland
Among the 51823 postmenopausal women in the Swedish Mammography Cohort, we investigated breast cancer risk in relation to
the FFQ-based estimated lignan intake by oestrogen receptor (ER) and progesterone receptor (PR) subtypes. A significant 17% risk
reduction for breast cancer overall in the high lignan quartile was observed, especially among PMH user (Pinteractiono0.010), but no
heterogeneity across ER/PR subtypes.
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Plant lignans, a major type of phytoestrogens in Nordic countries,
are mainly present in cereals, fruit, and vegetables (Adlercreutz,
1998a,b) and are metabolised to mammalian lignans (e.g.
enterolactone (ENL)) by the intestinal microflora (Adlercreutz,
2002). Since a preventive action of lignans against breast cancer
was suggested (Adlercreutz et al, 1982), this has been evaluated
in vitro (Welshons et al, 1987; Hirano et al, 1990; Mousavi and
Adlercreutz, 1992), in vivo (Serraino and Thompson, 1991, 1992)
and in clinical studies (Adlercreutz et al, 1988, 1991; Phipps et al,
1993; Thompson et al, 2005). Biological plausibility was discussed
in a recent review (Adlercreutz, 2007). Hormone-dependent
(Adlercreutz et al, 1992, 1993) and other mechanisms (Hirano
et al, 1990; Kitts et al, 1999; Ma ¨kela ¨ et al, 1999; Prasad, 2000;
Rickard et al, 2000) have been suggested. Six prospective (den
Tonkelaar et al, 2001; Keinan-Boker et al, 2004; Kilkkinen et al,
2004; Olsen et al, 2004; Touillaud et al, 2007; Verheus et al, 2007)
and six case–control studies (Pietinen et al, 2001; Dai et al, 2002;
McCann et al, 2002, 2004, 2006; Fink et al, 2007) have evaluated
the issue among postmenopausal women. Of these, only four
considered oestrogen and progesterone receptor status of tumours
(ER/PR) (den Tonkelaar et al, 2001; Olsen et al, 2004; McCann
et al, 2006; Touillaud et al, 2007). We therefore examined the issue
in a large population-based cohort study with stratification by
family history of breast cancer, level of alcohol intake, body mass
index, and use of postmenopausal hormone (PMH).
MATERIALS AND METHODS
The Swedish Mammography Cohort (SMC) was described
previously (Wolk et al, 1998; Suzuki et al, 2006). It was established
in 1987–90 that all women in Va ¨stmanland who were born in
1917–48, and in Uppsala born in 1914–48, were invited. A total of
66651 women completed a questionnaire including diet. In 1997, a
second questionnaire was sent to all cohort members. We excluded
those with missing or incorrect data, with previous cancer (except
non-melanoma skin cancer), who were not post-menopausal and
who were 70þ years old at baseline leaving a cohort of 51823
women. The information on diet was collected through self-
administrated food-frequency questionnaires in 1987 and 1997.
Total lignan intake were estimated using published values of
following four lignans; secoisolariciresinol, matairesinol, laricir-
esinol, and pinoresinol (Mazur et al, 1996, 1998a,b, 2000;
Adlercreutz and Mazur, 1997; Mazur and Adlercreutz, 1998;
Valsta et al, 2003; Milder et al, 2005; Penalvo et al, 2005; Schwartz
and Sontag, 2006; Thompson et al, 2006). Other nutrients
were calculated based on the Swedish National Food Administra-
tion database (Bergstro ¨m et al, 1991). Cereals (60%), vegetables
(27%), and fruits (10%) are the main sources of our lignans.
Among a random sample of 137 women from the cohort, the
correlation between the FFQ-based estimates of lignan intake and
serum ENL levels measured by time-resolved fluoroimmunoassay
(Adlercreutz et al, 1998) was r¼0.2 (Spearman’s rank). Date of
breast cancer diagnosis, death, or migration from the study area
were identified by linkage of the cohort through the Swedish
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yRegistration System. Information about receptor status of breast
tumours, measured by an Abbott immunoassay (Pousette et al,
1986) and an immunohistochemical method, was obtained from
Uppsala University Hospital and the Regional Oncology Centre.
The study was approved by the Regional Ethics Committee at the
Uppsala University Hospital and Karolinska Institute. We used
time-dependent multivariate Cox proportional hazards regression
model to estimate hazard rate ratios and 95% confidence intervals
with age as the time scale (Korn et al, 1997). We subdivided lignan
intakes into four categories based on approximate quartiles. Trend
tests were conducted by using the median value for each category
of lignans as a continuous variable. Heterogeneity in the results
between the ERþPRþ and other subtypes was evaluated using
the Wald statistic (Liao, 2004). P-value for interaction was
evaluated by a likelihood ratio test. Analyses were performed by
SAS system, version 9.1 (SAS Institute, Cary, NC, USA). Statistical
tests were two-sided, and significance levels defined as Po0.05.
RESULTS
Among 51823 women with an average 8.3-year follow-up, 1284
invasive breast cancer cases were diagnosed, with details of ER/PR
status available for 1188 cases. Of these, 716 were ERþPRþ, 279
ERþPR ,5 0E R  PRþ, and 143 ER PR  tumours. Women with
high lignan intake tended to be older, have more education and
have greater use of PMH (Table 1).
Overall, we observed a statistically significant inverse associa-
tion between lignan intake and breast cancer risk (Table 2).
Compared to women in the lowest quartile (o712mgday
 1), the
multivariable adjusted relative risks (RR) for the highest quartile
(X1036mgday
 1) were 0.83 (95% confidence interval¼0.70–0.97;
Ptrend¼0.042) for overall, 0.86 (0.69–1.08) for ERþPRþ, 0.77
(0.54–1.09) for ERþPR , 0.92(0.56–1.52) for ER PR . There
was no evidence for heterogeneity in the results between the
ERþPRþ and other subtypes (all PheterogeneitiesX0.65).
In the full adjusted analysis stratified by family history of breast
cancer, by levels of alcohol intake and by body mass index (o25 or
X25kg/m
2), there was no evidence for interaction with lignans
in relation to overall risk or of any subtype; all Pvalues for trends
were40.60 and all Pvalues for interaction40.35. We also observed a
significant inverse association of lignans with overall risk among
PMH ever-users; the multivariable adjusted RR for the highest
quartile of intake compared to the lowest was 46% lower
(Ptrend¼o0.0001; Table 3). In contrast, among PMH never-users,
no association was observed (Pinteraction¼0.01). The observed
interaction for PMH use seemed to be confined to ERþPRþ
tumors (Pinteraction¼0.016). There was no heterogeneity in the
results between ERþPRþ and other tumors (all Pheterogeneity
X0.21). Lignans were positively correlated with intake of fruits
and vegetables (r¼0.4) and of cereal, fruit and vegetable fibre
(r¼0.7, 0.2 and 0.4, respectively). After adjusting for these factors,
the result for lignans was slightly attenuated but still significant
among PMH user (Table 3).
DISCUSSION
In this large population-based prospective cohort of postmeno-
pausal women, we observed a significant inverse association
between lignan intake and overall breast cancer risk, especially
among PMH user. There was no evidence of heterogeneity across
ER/PR tumours. These results are similar to our previous study
with a significant inverse association between cereal fibre and
breast cancer risk among PMH users (Suzuki et al, 2008). The
estimated lignan intake was correlated with cereal fibre (r¼0.7)
but after adjusting for specific fibres, the association among PMH
users was still significant. This inverse association agrees with two
previous studies among postmenopausal women (Fink et al, 2007;
Touillaud et al, 2007). Non-significant inverse associations
(Pietinen et al, 2001; Dai et al, 2002; McCann et al, 2002, 2004;
Keinan-Boker et al, 2004; Olsen et al, 2004; Verheus et al, 2007)
and no association (den Tonkelaar et al, 2001; Kilkkinen et al,
2004; McCann et al, 2006) have also been reported.
An inverse association of lignans with risk has been reported
among premenopausal women (Dai et al, 2002; McCann et al, 2002,
2004, 2006; Linseisen et al, 2004; Piller et al, 2006a), among women
with palpable cysts (Boccardo et al, 2004), and high epidermal
growth factor concentrations (Boccardo et al, 2003), and among
those carrying the A2 allele of CYP17 (McCann et al, 2002;
Piller et al, 2006b) possibly associated with increased levels of
endogenous hormone (Haiman et al, 1999). Given these findings,
an inverse relation of risk with lignans is probable in subgroups of
women with high circulating oestrogen level just as discussed with
Table 1 Age-standardised
a characteristics of risk factors for breast cancer according to the levels of lignan intake among 51823 postmenopausal women
in the Swedish Mammography Cohort
b
Quartiles of estimated total lignan intake, lgday
 1
Q1 Q2 Q3 Q4
o712 712–866 867–1035 X1036
Characteristics n¼12 730 (24.6%) n¼13 030 (25.1%) n¼13 011 (25.1%) n¼13 052 (25.2%)
Intake of lignans, mgday
 1, median 613.6 791.8 942.7 1175.1
Age at entry, years, mean (s.d.) 59.1 (8.1) 59.1 (7.9) 59.6 (7.8) 60.6 (7.7)
Age at menarche, years, mean (s.d.) 13.2 (1.3) 13.2 (1.2) 13.2 (1.2) 13.2 (1.3)
Age at first birth, years, mean (s.d.) 23.9 (4.5) 24.2 (4.6) 24.2 (4.5) 24.1 (4.4)
Body mass index, kgm
 2, mean (s.d.) 25.2 (4.1) 25.2 (3.9) 25.1 (3.9) 25.1 (4.0)
Number of children, n, mean (s.d.) 2.1 (1.3) 2.2 (1.2) 2.1 (1.2) 2.1 (1.3)
Age at menopause, years, mean (s.d.) 50.6 (4.9) 50.8 (4.8) 50.9 (4.6) 50.8 (4.8)
X12 years of education, % 8.1 10.1 11.1 12.4
Ever use of oral contraceptives, % 53.5 54.3 54.8 54.2
Ever use of postmenopausal hormones, % 42.1 44.7 46.6 44.8
Family history of breast cancer, %
c 7.8 8.5 8.2 8.0
Total energy intake, kcalday
 1, mean (s.d.) 1532 (447) 1604 (428) 1616 (421) 1628 (465)
Total fat intake, gday
 1, mean (s.d.) 56.0 (8.3) 53.1 (7.5) 50.9 (7.6) 47.7 (8.3)
Alcohol intake, ethanol gday
 1, mean (s.d.) 3.2 (5.1) 3.6 (5.4) 3.5 (4.5) 3.1 (6.1)
s.d.¼standard deviation.
aAge-standardised to the distribution of person–time of follow-up among all study participants.
bBased on the information at 1987 and 1997.
cBreast
cancer in mother, sister, or daughter.
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biological mechanism is not clear, but in vitro studies also showed
that lignan ENL in the presence of oestrogens suppressed the
oestrogen-induced proliferation in MCF-7 breast cancer cell
(Mousavi and Adlercreutz, 1992) and stimulated the synthesis of
sex hormone-binding globulin in liver cells (Adlercreutz et al,
1992).
The lack of association among overweight women may be due
to the relatively high circulating oestrogen levels from PMH use
having a stronger effect than the endogenous oestrogens formed in
peripheral tissues (Cleland et al, 1985; Jurgens et al, 1992;
Hankinson et al, 1998). Compared to lean women, obese women
tend to have a lower prevalence of PMH use (Suzuki et al, 2006)
and lower level of plasma ENL (Kilkkinen et al, 2001; Johnsen et al,
2004). Body fat might attenuate the effect of lignans by suppressing
intestinal microflora activity (Nishizawa et al, 1988), or trapping
ENL (Johnsen et al, 2004).
Our finding for ERþPRþ tumours among PMH users partly
agrees with a prospective study (Touillaud et al, 2007), though
these results were not confined to PMH users. No association was
Table 2 Relative risks (RRs) and 95% confidence intervals for the association between FFQ-based estimated intake of lignans and postmenopausal breast
cancer risk by receptor-defined subtype among 51823 postmenopausal women in the Swedish Mammography Cohort
Quartiles of estimated total lignan intake, lgday
 1
Categories for quartile Q1 Q2 Q3 Q4
Lignan intake, lgday
 1 No. of cases o712 712–866 867–1035 X1036 P
a P
b
No of person-year 101994 105399 107791 115147
All invasive tumours
Age-adjusted RR 1284 1.00 0.86 (0.74–1.00) 0.87 (0.74–1.01) 0.86 (0.74–1.00) 0.09
Multivariable-adjusted RR
c 1284 1.00 0.83 (0.71-0.97) 0.83 (0.70-0.97) 0.83 (0.70-0.97) 0.042
ER+PR+tumours
Age-adjusted RR 716 1.00 0.82 (0.66-1.01) 0.90 (0.73-1.10) 0.89 (0.72-1.09) 0.44
Multivariable-adjusted RR
c 716 1.00 0.79 (0.63–0.97) 0.86 (0.69–1.06) 0.86 (0.69–1.08) 0.35
ER+PR tumours
Age-adjusted RR 279 1.00 0.81 (0.59-1.12) 0.67 (0.48-0.94) 0.77 (0.56-1.07) 0.09
Multivariable-adjusted RR
c 279 1.00 0.77 (0.56–1.07) 0.64 (0.45–0.90) 0.77 (0.54–1.09) 0.12 0.65
ER PR tumours
Age-adjusted RR 143 1.00 0.85 (0.53-1.36) 0.93 (0.59-1.46) 0.87 (0.55-1.38) 0.66
Multivariable-adjusted RR
c 143 1.00 0.87 (0.54–1.40) 0.96 (0.60–1.54) 0.92 (0.56–1.52) 0.86 0.99
ER, oestrogen receptor; PR, progesterone receptor.
aTwo sided P-values for trend were calculated using the Wald statistics using the median values for each category of intake of
lignan as continuous variable.
bP-values (two-sided) for heterogeneity from the Wald test compared with four pairs of b-coefficients of ER+PR+tumours.
cMultivariable Cox
proportional harzard models with age as the time-scales were adjusted for height (continuous), body mass index (o18.5, 18.5–24.9, 25–29.9, X30kgm
 2), education (o12
years of education, X12 years of education), parity (nulliparous, 1–2, X3), age at first birth (nulliparous, o26, 26–30, X31 years), age at menarche (p12, 13, X14 years,
missing), age at menopause (o51, X51 years), type of menopause (natural, surgery), use of oral contraceptives (ever, never, missing), use of postmenopausal hormones (ever,
never, missing), family history of breast cancer among first-degree relatives (yes/no), history of benign breast disease (yes/no), quintiles of total energy intake, quintiles of energy-
adjusted total fat intake, and alcohol intake (nondrinkers, o3.4, 3.4–9.9, X10.0 ethanol gday
 1).
Table 3 Multivariable relative risks (RRs) and 95% confidence intervals (CI) for the association between total lignan intake and all postmenopausal breast
cancer risk among 41795 postmenopausal women
a in the Swedish Mammography Cohort with stratified by use of PMH
Quartiles of estimated total lignan intake, lgday
 1
Q1 Q2 Q3 Q4
No of cases No Ref. No RR (95%CI) No RR (95%CI) No RR (95%CI) Ptrend
b Pint
c
Use of PMH
d
Ever 446 117 1.00 133 0.85 (0.66–1.10) 119 0.75 (0.57–0.98) 77 0.54 (0.39–0.73) o0.0001 o0.01
Never 528 139 1.00 109 0.72 (0.55–0.92) 127 0.85 (0.66–1.09) 153 0.97 (0.76–1.25) 0.69
Use of PMH
e
Ever 446 117 1.00 133 0.90 (0.68–1.19) 119 0.83 (0.59–1.17) 77 0.64 (0.42–0.99) 0.042 0.010
Never 528 139 1.00 109 0.80 (0.61–1.06) 127 1.06 (0.78–1.44) 153 1.26 (0.88–1.80) 0.07
aAmong 41 795 postmenopausal women with complete information for PMH use in the Swedish Mammography Cohort.
bTwo-sided P-values for trend were calculated using
the median values for each category of dietary lignan intake as continuous variable.
cTwo-sided P-values for interaction were calculated based on  2 log likelihood test based on
the model.
dMultivariable-adjusted RR adjusted for age (the time-scale), height (continuous), education (o12 years of education, X12 years of education), parity (nulliparous,
1–2,X3), age at first birth (nulliparous, o26, 26–30, X31 years), age at menarche (p12, 13, X14 years, missing), age at menopause (o51, X51 years), type of menopause
(natural, surgery), use of oral contraceptives (ever, never, missing), use of postmenopausal hormones (ever, never, missing), total energy intake (quintiles), energy adjusted total
fat intake (quintiles), alcohol intake (nondrinkers, o3.4, 3.4–9.9, X10.0).
eMultivariable-adjusted model as above further adjusted for consumption of fruits and vegetables
(quintiles), energy-adjusted dietary fibre intake (quintile; cereal, fruit, and vegetable fibre independently).
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Olsen et al, 2004) and a case–control study (McCann et al, 2006).
Some nutrient misclassification and individual variation in
intestinal microflora, as well as the lack of detailed information
about PMH use are all relevant. Lignan estimates were not highly
correlated with plasma ENL, but the observed correlation was
comparable to those reported previously (Kilkkinen et al, 2003;
Hedelin et al, 2006). In prospective cohort design, this misclassi-
fication of exposure tends to be nondifferential which may
attenuate the observed association toward null. Further studies
need to elucidate this issue with taking the circulating level of
oestrogens into consideration.
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